Bruker Co. (NASDAQ:BRKR) Receives $79.36 Consensus Target Price from Brokerages

Shares of Bruker Co. (NASDAQ:BRKR) have earned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $79.36.

A number of research analysts recently weighed in on the stock. TD Cowen lowered their target price on shares of Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research note on Wednesday, November 6th. Wolfe Research lowered Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. Wells Fargo & Company cut their target price on Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. Barclays lowered their price target on Bruker from $75.00 to $69.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. Finally, Citigroup cut their price objective on shares of Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, November 6th.

Institutional Trading of Bruker

Several hedge funds have recently made changes to their positions in BRKR. FMR LLC increased its stake in Bruker by 21.4% during the third quarter. FMR LLC now owns 14,306,122 shares of the medical research company’s stock worth $987,981,000 after acquiring an additional 2,521,904 shares during the last quarter. Marshall Wace LLP increased its position in shares of Bruker by 127.8% during the 2nd quarter. Marshall Wace LLP now owns 1,389,537 shares of the medical research company’s stock valued at $88,666,000 after purchasing an additional 779,549 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in Bruker during the 2nd quarter valued at $36,472,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Bruker by 1,933.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 410,234 shares of the medical research company’s stock worth $28,331,000 after buying an additional 390,057 shares during the period. Finally, AQR Capital Management LLC increased its position in Bruker by 123.6% during the second quarter. AQR Capital Management LLC now owns 555,468 shares of the medical research company’s stock valued at $35,444,000 after acquiring an additional 307,021 shares during the last quarter. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Bruker Trading Down 2.6 %

NASDAQ:BRKR opened at $54.49 on Friday. Bruker has a one year low of $54.33 and a one year high of $94.86. The business has a fifty day moving average price of $62.85 and a 200-day moving average price of $65.61. The firm has a market capitalization of $8.26 billion, a price-to-earnings ratio of 26.20, a price-to-earnings-growth ratio of 2.68 and a beta of 1.20. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). The company had revenue of $864.40 million during the quarter, compared to analysts’ expectations of $866.46 million. Bruker had a return on equity of 21.52% and a net margin of 9.41%. The business’s quarterly revenue was up 16.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.74 EPS. Sell-side analysts forecast that Bruker will post 2.4 EPS for the current year.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.